Nasdaq · Healthcare
MIMEDX GROUP, INC. (MDXG)
As-reported financials and recent SEC filings for MIMEDX GROUP, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$418.6M
Net income
$48.6M
Net margin
11.6%
Diluted EPS
$0.32
ROE
18.9%
P/E (TTM)
19.6×
Market cap
$585.4M
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $418.6M | $348.9M | $321.5M | $267.8M | $242.0M |
| Gross profit | $345.6M | $288.8M | $266.8M | $219.5M | $202.4M |
| Operating income | $63.9M | $58.9M | $37.1M | $-14.7M | $-7.1M |
| Net income | $48.6M | $42.4M | $58.2M | $-30.2M | $-10.3M |
| Diluted EPS | $0.32 | $0.28 | $0.37 | $-0.33 | $-0.15 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-25
View on EDGAR →8-K2026-06-16
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →DEFA14A2026-04-29
View on EDGAR →Go deeper on MDXG
Search MIMEDX GROUP, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.